VRDN

Viridian Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 0/10
  • Value↓ 1/10
Viridian Therapeutics sales and earnings growth
VRDN Growth
Low
  • Revenue Y/Y↑ 18621.82%
  • EPS Y/Y↓ -0.30%
  • FCF Y/Y↓ -8.37%
Viridian Therapeutics gross and profit margin trends
VRDN Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -508.50%
  • ROIC 5Y↓ -66.95%
Viridian Therapeutics net debt vs free cash flow
VRDN Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -45.1

Viridian Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks